Genoscience Pharma Is Innovating to Disrupt Cancer Treatment

We are conceptualizing and developing disruptive and innovative science from bench to bedside for improving the conditions of patients in serious unmet medical needs.

Learn More

Our Approach

As all human living cells, cancer cells need energy to self-renew and survive. Lysosome is a key compartment implicated in cancer cells survival. Among the acquired modifications in cancer cells, changes in lysosomal phenotype and functions are well described, making lysosome a target of interest for novel therapies. Genoscience Pharma focuses on new approaches based on the depriving of cancer cells from essential nutrients by disrupting lysosomal functions.

Discover

Our Pipeline

We leverage our deep knowledge of underlying biological processes to develop innovative and disruptive technology, with potent small molecule drug candidates that directly target lysosomal functions, implicated in the growth, spread and resistance of cancers. We retain global development and commercialization rights of GNS561.

Discover

News

News
Jan. 06 2023

Genoscience Pharma announces the start of GNS561’s Phase 2b Clinical Trial

Genoscience Pharma announces launch of phase 2b clinical trial of ezurpimtrostat (GNS561) to treat hepatocarcinoma…
Read More
News
27 October 2022

Prix Galien USA 2022: Genoscience Pharma is nominated in the category “Start-up/Biotech”

Genoscience Pharma has been nominated to the Prix Galien USA 2022 A so excited event…
Read More
News
13 September 2022

Orphan Drug Designation to GNS561 for the treatment of Cholangiocarcinoma to GENFIT

Genoscience Pharma is proud that FDA granted an Orphan Drug Designation to GNS561 (a Genoscience's…
Read More
View All News

Events

Events
22 April 2022

BIOTRINITY – LONDON – 26-27th April 2022

Genoscience Pharma is enthusiastic, after having selected , about presenting the company  during the Company…
Read More
Events
January 11-16, 2021

Biotech Showcase™ 2021

Biotech Showcase™ 2021_ Investor Digital Conference Excited to attend the 2021 Digital Investor Conference which…
Read More
Events
November 19-20, 2020

2020 Drugging Autophagy Summit

Genoscience Pharma has presented at The Drugging Autophagy Summit its Phase 1b results, where all…
Read More
View All Events

“Translating novel scientific insights into medicines for cancer patients”

Philippe Halfon, CEO of Genoscience Pharma